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INTRODUCTION
Rifampicin, a semisynthetic antibiotic, is known to
inhibit the bacterial DNA-dependent RNA polym-
erase (1), the growth of some animal viruses (2),
and the focus formation induced by oncogenic
viruses (3, 4). While certain derivatives of rif-
ampicin can inhibit the RNA-dependent DNA
polymerase activity of oncogenic viruses, and a
similar activity found in normal and virus-trans-
formed cells (5-7), rifampicin itself, when tested
in vitro, has no effect on the mammalian DNA-
dependent RNA polymerases (I) . Nevertheless,
toxicity of the drug for some cell lines has been re-
ported (8). Recently, rifampicin has been shown to
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suppress the humoral and cellular immune re-
sponse in vivo and in vitro (9) and to inhibit
thymidine incorporation by human lymphocytes
after stimulation by phytohemagglutinin (PHA)
and tuberculin (10) .
One of the earliest known events in lymphocyte
transformation by PHA is the stimulation of RNA
synthesis (11, 12) due to the increase in the activity
of RNA polymerases (13). Among the three RNA
polymerases examined, RNA polymerase I is stim-
ulated within 1 hr and RNA polymerase II after 1
hr of PHA treatment (13). In this communication,
I wish to present results correlating a block in
lymphocyte transformation with synthetic events
that follow soon after PHA stimulation.
515516
	
BRIEF NOTES
MATERIALS AND METHODS
Detailed descriptions of the nutrient media, prepara-
tion of human lymphocyte cultures from blood, and
other experimental methods have been published (12) .
Purified PHA (Burroughs Welcome & Co ., Inc.,
Tuckahoe, N. Y.) was added at the concentrations
recommended by Milthrop and Forsdyke (14) . Iso-
lation of nuclear fractions and assays for the three re-
spective RNA polymerases were detailed previously
(13), as were the DNA determinations using Burton's
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FIGURE 1 Effect of rifampicin on uridine incorporation into RNA by PHA-stimulated lymphocytes .
Samples containing 5 X 106 cells/ml were pretreated with PHA for 1 hr before 100 µg/ml of rifampicin
were added (0 time in the abscissa). At the times indicated, the cells were incubated with 4 µCi/ml of
uridine-3H (sp act 20 Ci/mmole) for 5 and 30 min and then processed for RNA determination and count-
ing. Fig. 1 A represents the incorporation of uridine- 3H into RNA after 5 min, and Fig. 1 B the incor-
poration after 30 min. •-0, PHA-treated lymphocytes ; a-a, PHA-treated lymphocytes plus rifam-
picin; and A-A, unstimulated lymphocytes.
method (15), RNA estimation by alkaline hydrolysis
(16), and protein by the procedure of Lowry et al .
(17) .
RESULTS
Inhibition of PHA-Induced Transformation
and DNA Synthesis by Rifampicin
To establish the effective concentration of
rifampicin required to block transformation and
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0DNA synthesis, antibiotic concentrations of 10-200
µg/ml were applied to cell cultures containing
5 X 106 cells/ml. The proportion of transformed
cells in the cultures was ascertained 5 days after
addition of PHA, and the rate of DNA synthesis,
measured as the incorporation of thymidine, after
72 hr. Addition of rifampicin at 100 .sg/ml resulted
in the presence of only 4% of transformed cells as
compared with 7070 in untreated companion
cultures. Concentrations of 100 and 200 µg/ml of
drug inhibited DNA synthesis by 70-90% . The
standard dose chosen for all subsequent experi-
ments was 100 µg/ml.
Effect of Rifampicin on RNA and
Protein Synthesis
Rates of RNA synthesis were measured by up-
take of uridine-3H into RNA. According to Cooper
(18), the RNA of lymphocytes, labeled during a 5
min pulse, sediments in a sucrose density gradient
as polydisperse material of heterogeneous molecu-
lar weight. By comparison, the RNA labeled
during a 30 min pulse sediments in the position of
ribosomes or ribosomal precursors. Therefore, two
intervals of incorporation were employed, of either
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5 or 30 min duration. Where appropriate, rifampi-
cin was added to the cells that had been pretreated
for 1 hr with PHA. At the times indicated in Fig . 1,
uridine-3H was added to the cultures, and the
incorporation of label into an RNA product was
determined. The results with 5-min pulses are
illustrated in Fig . I A, and with 30-min pulses in
Fig. I B, from which it is apparent that within 1 hr
after addition of rifampicin the drug inhibited syn-
thesis of the rapidly labeled RNA fraction . The
drug also inhibited synthesis of RNA formed dur-
ing the 30-min pulses within 2 hr after its applica-
tion. By comparison, 0.15 µg/ml of actinomycin D
failed to suppress RNA synthesis related to the 5
min uridine-3H pulse, but did inhibit by 75% the
synthesis of RNA formed during the 30-min pulses .
The influence of rifampicin on the synthesis of
protein, ascertained by incorporation of leucine-3H
into macromolecular form during 30-min intervals,
was also monitored at various times after exposure
of lymphocytes to PHA. The results, summarized
in Fig. 2, showed that the drug had either minimal
or no effect on protein synthesis during the first 3
hr after induction. Exposure to rifampicin for
longer periods resulted in a decline, until the level
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FIGURE 2 Effect of rifampicin on amino acid incorporation into proteins by PHA-stimulated lympho-
cytes. Samples containing 5 X 106 cells/ml were pretreated with PHA for 1 hr before 100 µg/ml of
rifampicin were added (0 time in the abscissa) . At the times indicated, the cells were transferred to a
leucine-less medium containing 2% fetal calf serum and 1 µCi/ml of L-leucine-4,5 3H (sp act 36 Ci/
mmole) and incubated for 30 min . The cells were washed with phosphate-buffered saline, precipitated
with 0.5 N perchloric acid (PCA) in the cold, washed with 0 .5 N PCA, 950 ]0 alcohol, and alcohol ether
(3 :1). The precipitates were resuspended in 0.1 N NaOH for protein determination and scintillation
counting.
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517of synthesis was suppressed to that observed with
unstimulated cells .
Effect of Rifampicin on the Nuclear
DNA-Dependent RNA Polymerases
The activity of the DNA-dependent RNA
polymerases was assayed in nuclear fractions .
Nuclei were isolated from cells that had been ex-
posed for varying time intervals to PHA plus
rifampicin. The data, summarized in Table I,
TABLE I
RNA Polymerase Activities in Isolated Nuclei from
PHA-Treated Cells Incubated with or without
Rifampicin and Control Cells (nmoles UMP- 3H/
mg DNA per 10 min)
Experimental conditions similar to those for Figs . I
and 2. At times indicated, 5 X 106/ml cells were
washed with phosphate-buffered saline, and then
resuspended in 1 ml of 0 .01 M Tris-HCl buffer
(Schwarz/Mann, Orangeburg, N . Y.), pH 7 .8,
with 1 MM MgC12 (or MnC12) and 10 mM KC1.
Swelling of the cells was allowed to proceed for 10
min at 4 °C. Triton X 100 was then added at a final
concentration of 0 .5%, and the cells were disrupted
by 10 strokes of a Dounce homogenizer and centri-
fuged at 800 g for 3 min. The pellet was washed with
the same solution plus 0.1% Na deoxycholate . The
nuclear fraction was then resuspended in 0 .25 tnl of
a mixture containing 0.3 M sucrose in 0.01 M Tris-
HCl buffer, pH 8 .0, 4 MM N1902 (or 1 .8 mm MnC12),
0.06 M NaCl, 30 mm 2-/3-mercaptoethanol, 0 .1 µmole
of adenosine triphosphate (ATP), cytidine triphos-
phate (CTP), guanosine triphosphate (GTP), and
0.03 µmole of 3H-labeled uridine triphosphate
(UTP) (sp act 20 )Xi/µmole) . The reaction was
allowed to proceed for 10 min at 37 °C and then
stopped by adding 5 ml of 10% trichloroacetic acid
(TCA) with 0.05 M sodium pyrophosphate . The pre-
cipitates were collected in Millipore filters, washed
twice with 10% TCA, and the radioactivity was de-
termined.
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showed that in the absence of rifampicin there
occurred the expected increase of RNA polym-
erase activity due to PHA induction (13) . Addi-
tion of the antibiotic inhibited the Mn++-depend-
ent enzyme activity (polymerase II) by 40% after
only 1 hr and by 74% after 24 hr of treatment. The
Mg++-dependent activity (polymerase I) was
reduced less, and the effect of rifampicin did not
become evident during the initial 3 hr of treatment.
DISCUSSION
The data presented indicate that rifampicin inhib-
its PHA-induced lymphocyte transformation and
interferes with RNA synthesis. Synthesis by PHA-
treated lymphocytes of rapidly labeled RNA, made
during 5-min pulses, is profoundly depressed soon
after exposure to rifampicin; but synthesis of the
ribosomal type of RNA, formed during the longer
30 min period of labeling, is suppressed later . The
inhibition of the latter type of RNA by actino-
mycin D relates it to transcription of ribosomal
genes that are GC rich and particularly sensitive to
actinomycin D. The observed reduction in protein
synthesis after 3 hr of rifampicin treatment is
consistent with the idea that inhibition of the
requisite PHA transcription precedes a reduction
in translation.
Inhibition of PHA-stimulated RNA synthesis in
lymphocytes indicates that the primary site of
rifampicin action, by analogy with bacterial and
certain animal viruses (1, 2, 19-22), is on the
induced RNA polymerases, particularly polym-
erase II . However, when assayed in vitro, the
mammalian enzymes are unaffected below a con-
centration of 200 µg (I). The discrepancy between
the in vitro and in vivo effects may result from (a)
an intracellular structural modification of rifampi-
cin, making it more active : this is the case of
manmade chemical modifications of the antibiotic
which result in very potent inhibitors of in vitro
transcription, for example, the compound PR 19
(3'-acetyl-I'-benzyl-2'-methylpyrrole [3,2-C]-
4-desoxyrifamycin SV) (W. Keller, personal
communication) ; or (b) altered configurational
relationship between the complex of template-
enzyme plus some factor(s) required for the initi-
ation of transcription ; they may be appropriate
for in vivo drug action, but are disturbed after
cell disruption. It is worth mentioning that in-
duction of RNA polymerase activities by PHA in
lymphocytes does not require protein synthesis,
indicating that the suppression of induced polym-
erase activities by rifampicin is not the result of
Time after
addition of
rifampicin
Conditions of PHA-
incubation treated cells
PHA-treated
cells
rifampicin
Control
cells
hr
1 Mg++ 2 .10 2 .12 1 .60
Mn++ 4 .20 2 .20 2 .00
3 Mg++ 4 .00 3 .20 1 .60
Mn++ 5 .40 3 .30 2 .30
6 Mg++ 6 .50 3 .80 1 .90
Mn++ 6 .80 2.00 1 .80
24 Mg++ 6 .20 3.90 2 .20
Mn++ 6 .00 2 .00 2 .50synthesis of proteins involved in the regulation of
the enzyme (13).
The 1 hr interval required for the onset of anti
biotic action may be related to the time required to
establish a critical intracellular concentration of
the drug. It can be shown that uptake of 14C_
labeled rifampicin by PHA-treated lymphocytes
occurs at a linear rate for about 2 hr and then
ceases (B. G. T. Pogo, unpublished results). The
effect of rifampicin may be related to its capacity
to enter the cell since incubation with PHA en-
hances the permeability of lymphocytes to a variety
of macromolecular precursors (23), and also ele-
vates threefold the uptake ofrifampicin 14C.
Recent reports have claimed that derivatives of
rifampicin inhibit an RNA-dependent DNA
polymerase of lymphocytes (5). Such an activity is
detected about 24 hr after exposure of cells to
PHA (24), i.e., at a much later time than the initial
stimulation of both RNA synthesis and enzyme
induction. There appears to be no direct relation-
ship between the action of rifampicin observed here
and inhibition of reverse transcriptase reported by
others.
The author is indebted to Dr. S. Dales for advice and
criticisms in the correction of the manuscript and to
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